Clinical trials: Stage IIIB Non-Small Cell Lung Cancer
Lung Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small…
- Trial name
- NCT00005093
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial…
- Trial name
- Geometry-N (NCT04926831)
- Testing
- capmatinib
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who…
- Trial name
- NCT00002911
- Testing
- marimastat
- Where
- 50 sites in United States, Canada
- Sponsor
- ILEX Oncology Services, Incorporated
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in…
- Trial name
- NCT01496742
- Testing
- RO5490258, bevacizumab [Avastin], cisplatin/carboplatin
- Where
- 87 sites in United States, Argentina and 11 more
- Volunteers
- 259 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
- Trial name
- NCT00766246
- Testing
- bevacizumab, docetaxel, carboplatin
- Volunteers
- 125 people
- Sponsor
- Pharmatech
Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine…
- Trial name
- ESSENCE (NCT01667562)
- Testing
- Erlotinib
- Where
- 4 sites in Serbia
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061854
- Testing
- soblidotin
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV…
- Trial name
- NCT01519804
- Testing
- cisplatin/carboplatin, onartuzumab, paclitaxel
- Where
- 69 sites in United States, Argentina and 7 more
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC).
- Trial name
- NCT01362400
- Testing
- IPI 504 plus Docetaxel
- Where
- 65 sites in United States, Hungary and 4 more
- Volunteers
- 226 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
NSCLC, NSCLC Stage IV
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic…
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer
- Trial name
- NCT05652868
- Testing
- MYTX-011
- Where
- 55 sites in United States, Australia and 5 more
- Volunteers
- 227 people
- Sponsor
- Mythic Therapeutics
Non-small Cell Lung Cancer
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
This study was designed to determine the safety and tolerability of PB101 (autologous NK cell product) in combination with standard of care EGFR-TKI in patients with EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT07271446
- Testing
- PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Precision Biotech Taiwan Corp.
NSCLC Stage IIIB, NSCLC Stage IV
Phase I Study of SPH1188-11 in NSCLC
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment.
- Trial name
- SPH1188-11 (NCT03231475)
- Testing
- SPH1188-11
- Where
- China
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Carcinoma, Squamous Cell
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To assess the response rate to induction therapy with docetaxel/CDDP. Secondary objectives: To assess Resectability after induction therapy Time to progression Overall survival Safety profile Quality of Life
- Trial name
- NCT00432315
- Testing
- Docetaxel + CDDP
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC)
AK129 Combination Therapy for Advanced Solid Tumors
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129…
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
- Trial name
- NCT06943820
- Testing
- AK129(dose 1), Pemetrexed, Paclitaxel
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Akeso
Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous…
- Trial name
- CheckMate 169 (NCT02475382)
- Testing
- Nivolumab
- Where
- 50 sites in Brazil, Canada
- Sponsor
- Bristol-Myers Squibb
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05498389
- Testing
- EMB-01, Osimertinib
- Where
- 3 sites in United States, China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Lung Neoplasms
Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
The Primary Objective is to evaluate the progression-free survival (PFS). The secondary objectives are: To compare the disease control rates of different doses of Docetaxel+Cisplatin as first-line treatment according to Response…
- Trial name
- TFINE (NCT01038661)
- Testing
- Docetaxel, Cisplatin, Best supportive care (BSC)
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00970580
- Testing
- BIIB022 With Paclitaxel and Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Biogen